Research programme: DNA replication enzyme inhibitors - Achillion Pharmaceuticals

Drug Profile

Research programme: DNA replication enzyme inhibitors - Achillion Pharmaceuticals

Alternative Names: ACH-2881; ACH-702

Latest Information Update: 25 Jun 2013

Price : $50

At a glance

  • Originator Achillion Pharmaceuticals
  • Class Quinolones; Small molecules; Thiazoles
  • Mechanism of Action DNA gyrase inhibitors; DNA primase inhibitors; DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Bacterial infections; Nosocomial infections

Most Recent Events

  • 25 Jun 2013 This programme is still active
  • 31 Dec 2010 DNA replication enzyme inhibitors developed under this research programme are available for licensing as of 31 Dec 2010. http://www.achillion.com
  • 26 Mar 2010 Achillion receives SBIR grant from NIH for antibacterial agent development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top